SION
Live chart
What they do
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
For information only · Important disclosures
Grades vs sector
No sector grades for SION yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.65 | -0.66 | -2.0% |
| 2026-05-12 | -0.50 | -0.60 | -19.1% |
| 2026-03-02 | -0.53 | -0.46 | +14.0% |
| 2025-11-05 | -0.47 | -0.46 | +3.2% |
| 2025-08-11 | -0.45 | -0.41 | +9.6% |
| 2025-05-12 | -0.45 | -0.62 | -37.8% |
| 2025-03-20 | -2.68 | -3.38 | -26.1% |
Insider trades
$252.1K
$21.6M
–
–
–
–
Stats refreshed 2026-10-21 17:58:56 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026